Technical Analysis for LXEO - Lexeo Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 50 DMA | Bullish | -0.07% | |
| Upper Bollinger Band Walk | Strength | -0.07% | |
| Upper Bollinger Band Touch | Strength | -0.07% | |
| MACD Bullish Centerline Cross | Bullish | 2.95% | |
| Upper Bollinger Band Walk | Strength | 2.95% | |
| Fell Below 50 DMA | Bearish | 6.24% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 7 hours ago |
| Upper Bollinger Band Resistance | about 7 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Rose Above Upper Bollinger Band | about 10 hours ago |
| Up 5% | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/28/2024
Lexeo Therapeutics, Inc. Description
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Rare Diseases Gene Therapy Applied Genetics Cardiomyopathy Lipid Storage Disorders Ataxia Friedreich's Ataxia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.33 |
| 52 Week Low | 9.0 |
| Average Volume | 133,885 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 13.76 |
| 20-Day Moving Average | 12.89 |
| 10-Day Moving Average | 13.47 |
| Average True Range | 1.05 |
| RSI (14) | 56.14 |
| ADX | 26.9 |
| +DI | 37.28 |
| -DI | 10.62 |
| Chandelier Exit (Long, 3 ATRs) | 13.65 |
| Chandelier Exit (Short, 3 ATRs) | 14.71 |
| Upper Bollinger Bands | 14.34 |
| Lower Bollinger Band | 11.45 |
| Percent B (%b) | 0.87 |
| BandWidth | 22.39 |
| MACD Line | 0.12 |
| MACD Signal Line | -0.11 |
| MACD Histogram | 0.222 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.85 | ||||
| Resistance 3 (R3) | 15.99 | 15.49 | 15.54 | ||
| Resistance 2 (R2) | 15.49 | 15.01 | 15.43 | 15.43 | |
| Resistance 1 (R1) | 14.73 | 14.71 | 14.48 | 14.59 | 15.32 |
| Pivot Point | 14.23 | 14.23 | 14.11 | 14.17 | 14.23 |
| Support 1 (S1) | 13.47 | 13.75 | 13.22 | 13.33 | 12.60 |
| Support 2 (S2) | 12.97 | 13.45 | 12.91 | 12.49 | |
| Support 3 (S3) | 12.21 | 12.97 | 12.39 | ||
| Support 4 (S4) | 12.07 |
